· Vision and Mission
With “excellent” disclosure quality, Qizheng Tibetan Medicine has received an “A” rating in the Shenzhen Stock Exchange’s disclosure assessment for seven consecutive years.
Release time:
2022-07-05 17:00
On July 4, the Shenzhen Stock Exchange released the “Notice on the 2021 Annual Information Disclosure Assessment Results for Listed Companies in the Shenzhen Market,” in which Qizheng Tibetan Medicine received an “A” rating. This marks the seventh consecutive year that the company has earned an “A” rating in the Shenzhen Stock Exchange’s information disclosure assessment.
It is reported that the Shenzhen Stock Exchange’s current assessment is based on “Guidance No. 11 on Self-Regulatory Supervision of Listed Companies—Assessment of Information Disclosure Work,” and, in light of regulatory practice and investor concerns, further intensifies its evaluation of listed companies’ cash dividends and share repurchases, investor relations management, fulfillment of social responsibilities, and other related areas, thereby strengthening the positive guiding role of information disclosure assessments.
The report shows that in 2021, the Shenzhen Stock Exchange conducted a comprehensive assessment of the information disclosure practices of a total of 2,553 listed companies. Among these companies, 454—accounting for 17.78%—received an A rating; 215 companies—representing 8.42%—have maintained an A rating for three consecutive years or more; and 121 companies—accounting for 4.74%—have maintained an A rating for five consecutive years or more.
Qizheng Tibetan Medicine takes “Doing Good and Benefiting Others, Pursuing Righteousness and Honest Business Practices” as its core corporate values and is guided by the concept of sustainable development. Since its IPO in 2009, the company has consistently been committed to putting into practice the philosophy of long-term value investing and effectively safeguarding investors’ rights and interests. The company strictly complies with regulatory requirements, continuously improves its standardized operational procedures, and ensures that all external information disclosures are truthful, accurate, complete, and timely. In 2021, the company issued 181 disclosure announcements and promptly responded to 100 investor inquiries via the Interactive Easy platform, earning the title of “Company with the Most Investor Relations Value of the Year” in the inaugural China Listed Companies Investor Relations Value Jinglun Awards.
Reporting media: Shanghai Securities Journal·China Securities Network
Report link: https://ggjd.cnstock.com/company/scp_ggjd/tjd_bbdj/202207/4914196.htm
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO